Medispec (M) Sdn Bhd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Medispec (M) Sdn Bhd - overview
Established
1992
Location
-, Penang, Malaysia
Primary Industry
Food
About
Based in Malaysia, and founded in 1992, Medispec (M) Sdn Bhd Medispec operates under Vitamode, a distributor of local pharmaceutical and supplement products in Malaysia. The company has a 4-story building and units in Petaling Jaya, which serves as the Strategic & Logistics Center of Medispec and the Ipoh sales office employing 100 staff. The company markets more than 100 pharmaceutical drugs and 30 health supplements in both prescription and over-the-counter (OTC) categories. In 2021, Ekuiti Nasional Berhad acquired a controlling stake in the company.
Medispec (M) Sdn Bhd distributes prescription drugs, proprietary drugs, and toiletries with Vitamode as a brand of nutritional supplement products that includes CoQ10 Ubiquinol, Mecobin, Lacidofil, Cognipro, and Tumecap. The company also serves as a bridge between drug manufacturers and consumers by marketing their pharmaceutical and healthcare products with the use of the Market Intelligence System (IMS) for the date market information. The company plans to take their brand regionally to ASEAN countries by leveraging Ekuinas’ expertise.
Current Investors
Ekuiti Nasional Berhad
Primary Industry
Food
Sub Industries
Health Foods & Nutritional Supplements, Pharmaceuticals
Website
www.medispec.com.my
Total Amount Raised
Subscriber access only
Medispec (M) Sdn Bhd - timeline of key events
Medispec (M) Sdn Bhd - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 27,184,503 | 34,396,192 | 45,439,864 | 56,927,313 | 60,852,374 | - | - | - | 64,252,994 | 70,904,878 | - | - | - |
| % Revenue Growth (YoY) | - | 26.5% | 32.1% | 25.3% | 6.9% | - | - | - | - | 10.4% | - | - | - |
| EBITDA (USD) | 6,690,813 | 8,951,993 | 12,431,369 | 14,938,043 | 12,165,634 | - | - | - | 7,610,692 | 10,997,698 | - | - | - |
| Operating Income (USD) | 6,029,718 | 8,066,190 | 11,343,102 | 13,911,674 | 11,139,265 | - | - | - | 6,312,688 | 9,995,701 | - | - | - |
| Operating Margin | 22.2% | 23.5% | 25.0% | 24.4% | 18.3% | - | - | - | 9.8% | 14.1% | - | - | - |
| % EBITDA Margin | 24.6% | 26.0% | 27.4% | 26.2% | 20.0% | - | - | - | 11.8% | 15.5% | - | - | - |
| NET Income (USD) | 4,066,333 | 5,424,801 | 8,010,431 | 9,997,649 | 7,320,699 | - | - | - | 4,444,268 | 7,300,937 | - | - | - |
| % Net Margin | 15.0% | 15.8% | 17.6% | 17.6% | 12.0% | - | - | - | 6.9% | 10.3% | - | - | - |
Medispec (M) Sdn Bhd - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Completed | Medispec (M) Sdn Bhd | - |
Displaying 1 - 1 of 1
Medispec (M) Sdn Bhd - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.